OPKO Health Schedules Third Quarter 2026 Earnings Release
OPKO Health, Inc. announced it will report its financial and operating results for the third quarter of 2026 on November 4, 2026.
Stocks · News reference
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
OPKO Health announced that its subsidiary, OPKO Biologics, has initiated a first-in-human Phase 1/2a clinical trial for OPK-8801001, a long-acting growth hormone receptor antagonist for acromegaly.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4
Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:OPK) with a Overweight and raises the price target from $3 to $4.